Skin Disorders News

Tralokinumab improved epidermal pathology, reduced inflammation and changed significant skin biomarkers in patients with atopic dermatitis, according to a study published in The European Journal of Allergy and Clinical Immunology.

Dupilumab showed continuous efficacy and safety in the long-term treatment of atopic dermatitis, according to a study.

Delgocitinib cream has shown efficacy in the treatment of hand eczema in two phase 3 trials.

Cendakimab was effective and generally safe in the treatment of moderate to severe atopic dermatitis in adults, according to a press release.

Omalizumab is effective and safe for the treatment of chronic urticaria, demonstrating high discontinuation due to well-controlled disease, according to a study.

Patients with cold urticaria and symptomatic dermographism experienced clinically meaningful and statistically significant complete responses with barzolvolimab, according to a webinar by Celldex Therapeutics.

A new imaging device effectively monitored skin texture changes in patients with skin of color with atopic dermatitis and xerosis following a prebiotic skincare regimen, according to a study.

New results evaluating the efficacy and safety of nemolizumab for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis were published in The Lancet, Galderma announced in a press release.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of Anzupgo for the treatment of chronic hand eczema in adults, LEO Pharma announced in a press release.

Responses to baricitinib and dupilumab were notable and similar among patients with moderate to severe atopic dermatitis in a real-world setting, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.